Select publications

André T et al. Phase II study of an optimized 5FU-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. Proc ASCO 2004;Abstract 3554.

André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

André T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003;21(15):2896-903. Abstract

Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract

de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47. Abstract

de Gramont A et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc ASCO 2004;Abstract 3525.

de Gramont A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15(2):808-15. Abstract

Giantonio BJ et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO GI Cancer Symposium 2003;Abstract 241.

Hickish T et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. Proc ASCO 2004;Abstract 3619.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Mabro M et al. Irinotecan, 5-fluorouracil infusion and leucovorin, (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer: Results of a multicenter phase II study. Proc ASCO 2003;Abstract 1125.

Sargent DJ et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc ASCO 2004;Abstract 3502.

Scheithauer W et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21(7):1307-12. Abstract